Skip to main content
. 2019 Apr 3;20(7):1665. doi: 10.3390/ijms20071665

Figure 3.

Figure 3

Circulating miRNA signatures of patients with cancer. (A) The miRNA signatures of patients with cancer before the initiation of hydromorphone treatment (i.e., day 1). The heat map of hierarchically clustered −ΔCq values for MOR-UP and MOR-DOWN miRNAs is presented; yellow and blue represent high and low blood miRNA levels, respectively. The MOR signal score is calculated from the subtraction of the sum of ΔCq for MOR-UP miRNAs from the ΔCq of the MOR-DOWN miRNAs. The patients with high and low MOR signal score values were classified into class 1 and class 2, respectively. The overall trend was that class 1 patients had higher ΔVAS scores than class 2 patients. (B) The putative model for the relationship between the MOR signal score and the potential for hydromorphone to exert analgesic efficacy.